Literature DB >> 7646465

Large variations in the proteolytic formation of a chromogranin A-derived peptide (GE-25) in neuroendocrine tissues.

R Kirchmair1, B Leitner, R Fischer-Colbrie, J Marksteiner, R Hogue-Angeletti, H Winkler.   

Abstract

We have established a radioimmunoassay for GE-25, a peptide present in the C-terminal end of the primary amino acid sequence of chromogranin A where it is flanked by typical proteolytic cleavage sites. Gel-filtration HPLC was used to characterize the molecular sizes of the immunoreactive molecules. The antiserum recognized not only the free peptide but also larger precursors including the proprotein chromogranin A. The tissues with the highest levels of GE-25 immunoreactivity were in decreasing order: the adrenal medulla, the three lobes of the pituitary gland, intestinal mucosa, pancreas and various brain regions. In adrenal medulla and parathyroid gland most of the immunoreactivity was found to be present as intact chromogranin A and some intermediate-sized peptides, without significant amounts of the free peptide. In anterior pituitary, and even more so in intestine, a shift to smaller peptides was seen. In the posterior and intermediate pituitary and in pancreas the predominant immunoreactive material was apparently represented by the free peptide GE-25. In reverse-phase chromatography this peptide eluted exactly like the synthetic standard, which allows a tentative identification as GE-25. In brain tissue the processing of chromogranin A was intermediate, with significant amounts of immunoreactivity corresponding to GE-25 as well as precursor proteins being present. We suggest that in those organs (endocrine pancreas, intermediate and posterior pituitary) where the major hormones are proteolytically processed there is also a concomitant proteolysis of further susceptible peptides. Since GE-25 is apparently formed in vivo and is well conserved between species it seems a good candidate for having specific physiological functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646465      PMCID: PMC1135892          DOI: 10.1042/bj3100331

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  53 in total

1.  Isolation and primary structure of a novel chromogranin A-derived peptide, WE-14, from a human midgut carcinoid tumour.

Authors:  W J Curry; C Shaw; C F Johnston; L Thim; K D Buchanan
Journal:  FEBS Lett       Date:  1992-04-27       Impact factor: 4.124

2.  Immunological characterization of secretory proteins of chromaffin granules: chromogranins A, chromogranins B, and enkephalin-containing peptides.

Authors:  R Fischer-Colbrie; I Frischenschlager
Journal:  J Neurochem       Date:  1985-06       Impact factor: 5.372

3.  Different degrees of processing of secretogranin II in large dense core vesicles of bovine adrenal medulla and sympathetic axons correlate with their content of soluble PC1 and PC2.

Authors:  C Egger; R Kirchmair; R Hogue-Angeletti; R Fischer-Colbrie; H Winkler
Journal:  Neurosci Lett       Date:  1993-09-03       Impact factor: 3.046

4.  Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues.

Authors:  A Iacangelo; H U Affolter; L E Eiden; E Herbert; M Grimes
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

5.  Secretoneurin--a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C).

Authors:  R Kirchmair; R Hogue-Angeletti; J Gutierrez; R Fischer-Colbrie; H Winkler
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

6.  Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites.

Authors:  M H Metz-Boutigue; P Garcia-Sablone; R Hogue-Angeletti; D Aunis
Journal:  Eur J Biochem       Date:  1993-10-01

7.  Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum.

Authors:  D T O'Connor
Journal:  Regul Pept       Date:  1983-07

8.  Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion.

Authors:  B H Fasciotto; C A Trauss; G H Greeley; D V Cohn
Journal:  Endocrinology       Date:  1993-08       Impact factor: 4.736

9.  Sites of synthesis of chromogranins A and B in the human brain.

Authors:  J D Erickson; R Lloyd; J Q Trojanowski; A Iacangelo; E Eiden
Journal:  Neuropeptides       Date:  1992-04       Impact factor: 3.286

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more
  5 in total

1.  Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.

Authors:  S K Mahata; D T O'Connor; M Mahata; S H Yoo; L Taupenot; H Wu; B M Gill; R J Parmer
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

2.  Processing of chromogranins in chromaffin cell culture: effects of reserpine and alpha-methyl-p-tyrosine.

Authors:  M Wolkersdorfer; A Laslop; C Lazure; R Fischer-Colbrie; H Winkler
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

3.  Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.

Authors:  Andreas Tartaglia; Guida M Portela-Gomes; Kjell Oberg; Paolo Vezzadini; Maria P Foschini; Mats Stridsberg
Journal:  Virchows Arch       Date:  2006-01-12       Impact factor: 4.064

4.  Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.

Authors:  Long Jin; Shuya Zhang; Jill Bayliss; Bernd Scheithauer; Xiang Qian; Ikuo Kobayashi; Mats Stridsberg; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  Ovulatory Induction of SCG2 in Human, Nonhuman Primate, and Rodent Granulosa Cells Stimulates Ovarian Angiogenesis.

Authors:  Patrick R Hannon; Diane M Duffy; Katherine L Rosewell; Mats Brännström; James W Akin; Thomas E Curry
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.